Nitrite-derived nitric oxide reduces hypoxia-inducible factor 1 -mediated extracellular vesicle α production by endothelial cells.
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Introduction 68
The production of extracellular vesicles (EVs) is a common feature of eukaryotic cells, including 69 platelets, leukocytes, and endothelial cells [1] . EVs are spherical, submicron structures enclosed by a 70 phospholipid bilayer, containing a variety of proteins, mRNAs and microRNAs [2] . Their application 71 to modulate physiology is complex, with evidence for them both augmenting and alleviating disease, 72
depending on their cellular origin and subsequent biophysical composition [3] . Elevated levels of EVs 73 have been shown to have pathophysiological roles in a plethora of disease states, including cancer [4-74 6], neurodegenerative disorders [7-10], and cardiovascular disease [11] [12] [13] . Specifically, endothelial 75 cell derived EVs have been shown to express tissue factor, suggesting a role in augmenting the 76 coagulation cascade [14] . Additionally, EVs from patients with myocardial infarction have been 77
shown to induce endothelial dysfunction ex vivo [15] . It has recently been shown that endothelial 78 cells enhance EV secretion following temporary hypoxia exposure in vivo [16, 17] , a fundamental 79 feature of the aforementioned diseases and resulting pathologies [18] [19] [20] . Indeed, EVs derived from 80 endothelial cells exposed to hypoxia have been shown to produce a markedly altered RNA and protein 81 composition, although the function of these EVs remains undetermined [21] . 82
The adaptation of cellular physiology in response to hypoxia is largely mediated by the transcription 83 factor hypoxia-inducible factor (HIF)-1, which promotes the transcription of genes involved in cell 84 proliferation, metastasis, angiogenesis, and vascular remodelling [22, 23] . HIF is comprised of an 85 oxygen regulated HIF-α subunit (HIF-1α or HIF-2α) and the constitutively expressed HIF-1β. Whilst 86 HIF-1α is ubiquitously expressed, HIF-2α is detected predominantly in vascular endothelial cells [24] . 87
The HIF-α subunit is targeted for degradation under normoxic conditions by the O2-dependent HIF-α 88 prolyl hydroxylase enzymes. These enzymes hydroxylate two conserved prolyl residues (Pro 564 and 89 Pro402) in the central oxygen-dependent degradation domain of the HIF-α subunit (both HIF-1α and 90 HIF-2α), which promotes the binding of the Von Hippel-Lindau protein, allowing ubiquitination and 91 subsequent degradation [25, 26] . Inhibition of these enzymes in hypoxia prevents the degradation of 92 HIF-α, allowing regulation of its transcriptional target genes [25] . HIF has been shown to increase 93 expression of several proteins involved in cytoskeletal changes [27] , a mechanism thought to be 94 implicated in augmented EV release [28] . Thus, selective targeting and modulation of HIF-α could 95 modulate endothelial cell EV release. 96
Endothelial-derived nitric oxide (NO) plays a pivotal role in vascular homeostasis, highlighted by the 97 deficiency of NO prevalent in cardiovascular disease states [29] . NO can modulate the cellular 98 response to hypoxia by preventing the stabilization of HIF-α via an increase in prolyl hydroxylase-99 mediated degradation [30, 31] . Previously, impaired endogenous NO production in HUVECs has been 100 shown to increase EV formation [32] . Recently, the inorganic anions nitrate (NO3 -) and nitrite (NO2 -), 101 once thought to be inert end products of NO metabolism, have been shown to be bioactive reservoirs 102 for NO bioactivity, particularly during hypoxia [33, 34] . NO3is reduced to NO2via commensal 103 bacteria present in the oral cavity. NO2can subsequently be reduced through reaction with various 104 proteins that possess NO2reductase activity, including Xanthine Oxidoreductase (XOR) [35, 36] , 105 heme globins [37, 38] , and components of the mitochondrial electron transport chain [39, 40] . 106
Here, we aimed to elucidate the role of both HIF-1α and HIF-2α in endothelial EV release, and 107 selectively target their expression in hypoxia via sodium nitrite (NaNO2) addition, and investigate the 108 effect on endothelial cell EV production. 109
Methods 110

Cell culture & viability 111
Human (HECV) endothelial cells were purchased from Interlab Cell Line Collection (ICLC, Naples, 112
Italy Aldrich, UK). HUVECs were used at passage 0 and not sub-cultured. Cells were cultured using T25 122 cm 2 flasks (Cellstar®, Greiner Bio-One, Germany) and maintained in an incubator at 37 °C and 5% 123 CO2. Cell counts were undertaken using trypan blue exclusion (1:1 v/v) and a Cellometer Auto T4 124 (Nexcelom Biosciences, USA). Cell viability and apoptosis were determined using MTS and Caspase-125
Glo 3/7 assays (Promega, Southampton, UK), respectively, according to the manufacturers' 126 instructions. 127
Hypoxia exposure 128
Hypoxic experiments were performed using an I-CO2N2 regulated InVivo 400 hypoxia workstation 129 (Ruskinn, Bridgend, UK). Upon cells reaching ~80% confluency, culture medium was removed. 130
HECVs were washed with phosphate-buffered saline (PBS) (Fisher Scientific, UK) and incubated 131 with 10 mL EV-free serum free medium (SFM) for 24-hours. Cells were cultured at either normoxia 132 (21% O2, 5% CO2, 37 °C) or hypoxia (1-20% O2, 5% CO2, 37 °C). The hypoxia mimetic agent 133 desferrioxamine was added (100 µM) to HECVs incubated in normoxia to confirm the role of hypoxia 134 in EV formation. 135
Extracellular vesicle isolation 136
EVs were isolated direct from cell culture as previously described [42] . Cells were cultured in serum-137 free medium (SFM) for 24 hours prior to EV isolation to avoid contamination from foetal calf serum. 138
Cell culture medium was extracted direct from the culture flask and subjected to differential ultra-139 centrifugation. Culture medium was spun at 500 × g for 10 min to remove any cells in suspension. 140
The supernatant was then centrifuged at 15,000 × g for 15 min to remove any cell debris. Finally, 141 supernatants were ultracentrifuged at 100,000 × g for 60 min to pellet EVs. This pellet was then 142 resuspended in 1 x sterile PBS, stored at 4°C and analysed within 1 week of isolation. 143
EV size and concentration analysis 144
Size and concentration distributions of EVs were determined using nanoparticle tracking analysis 145 (NTA, NanoSight LM10 system, UK) as described previously [43] . NTA is a laser illuminated 146 microscopic technique equipped with a 642 nm laser and a high sensitivity digital camera system 147 (OrcaFlash2.8, Hamamatsu, NanoSight Ltd) that determines the Brownian motion of nanoparticles in 148 real-time to assess size and concentration. Sixty-second videos were recorded and particle movement 149 was analysed using NTA software (version 2.3). Camera shutter speed was fixed at 30.01 ms and 150 camera gain to 500. Camera sensitivity and detection threshold were (11-14) and (4-6), respectively. 151
A representative NTA trace can be seen in Appendix Figure A1 . EV samples were diluted in EV-free 152 sterile water (Fresenius Kabi, Runcorn, UK). Samples were run in quintuplicate, from which EV 153 distribution, size and average concentration were calculated. EV concentrations were then normalised 154
to cell count and expressed as EVs/cell. For HIF-2α silencing, the siRNA duplex was mixed with siRNA transfection reagent (Santa Cruz 164 Biotechnology, USA) (1:1 ratio) in transfection medium and incubated at room temperature for 30 165 minutes before being added onto the cells. Cells were incubated for 5 hours before 2x DMEM (20% 166 FCS, 2% P/S) was added. Cells were incubated for an additional 24 hours before replacing the 167 medium with fresh 1x DMEM (10% FCS, 1% P/S). Cells were incubated for an additional 48-72 168 hours prior to hypoxia exposure for 24 hours. 169
Nitrite treatment and xanthine oxidoreductase inhibition 170
Preliminary experiments established a NaNO2 dose-effect curve (0.3-300 µM) where 30µM was 171 discovered to be the optimal dose and was used for all subsequent experiments (Appendix Figure A2 ). 172
Cells were incubated in either hypoxia (1% O2), or normoxia for 24-hours. Allopurinol (100 µM) was 173 added to inhibit the hypoxia mediated reduction of NO2to NO by xanthine oxidoreductase in HECVs 174 exposed to hypoxia for 24 hours. The NO donor S-Nitrosoglutathione (GSNO, 10 µM) was also 175 added to cells to confirm the effect of NO on EV production. 176
Western blot 177
HECVs were washed with phosphate-buffered saline (PBS) and lysed in ice-cold Pierce® RIPA lysis 178 buffer (ThermoFisher, UK). The lysates underwent centrifugation at 13,000 x g for 20 min at 4 °C. 179
The supernatants were collected and their protein concentrations were determined by a Pierce® BCA 180
Protein Assay Kit (ThermoFisher, UK), measured on a BMG CLARIOstar (BMG Labtech, UK). Cell 181 homogenates (80 µg protein) were separated by a 10% sodium dodecyl sulfate-polyacrylamide gel 182 (SDS-PAGE) and transferred to a nitrocellulose membrane. After blots had been washed with TBST 183 (10 mM Tris, 150 mM NaCl, 0.05% Tween-20; pH 7.6) the membrane was blocked with 5% 184 skimmed milk powder in TBST for 1 hour and incubated overnight at 4 °C with a purified mouse 185 monoclonal antibody against human HIF-1α (BD Biosciences, UK), HIF-2α (Santa Cruz, USA) or a 186 rabbit monoclonal antibody against β-actin (Sigma-Aldrich, UK) at dilutions recommended by the 187 manufacturers. The membranes were washed and then incubated for 1 hour with the required 188 secondary IgG horseradish peroxidase labelled antibody (goat anti-mouse or goat anti-rabbit). 189
Detection was performed using West Femto chemiluminescence detection reagent (Pierce and Warner 190
Ltd, UK) and exposed to photographic film (Amersham™ Hyperfilm, GE Healthcare) in a dark room. 191
Films were developed using Kodak™ -D19 developer and fixer (Sigma-Aldrich). 192
Electron microscopy 193
Scanning electron microscopy (EM) images were generated to confirm EV release under normoxic 194 and hypoxic (1% O2) conditions. HECVs were washed in PBS and fixed in glutaraldehyde Aldrich, UK) in Sorensen's phosphate buffer (1% v/v) at room temperature for 1 hour. Samples were 196 then dehydrated through graded isopropanol at 50, 70, 90 and 100% for 10 minutes each, followed by 197 three exchanges in hexamethyldisilazane (Sigma-Aldrich, UK). Samples were then air dried and 198 splutter-coated with gold and viewed at 5kV using a JEOL 840A scanning electron microscope (JEOL 199 Tokyo, Japan). 200
Isolated EVs were visualised using transmission EM. Isolated EVs in PBS were negatively stained by 201 placing carbon-coated grids onto 50 μL droplet of reagent for 30 minutes. Vesicles were fixed in 1% 202 glutaraldehyde in Sorensen's phosphate buffer (1:1 v/v) for 10 minutes at room temperature. Grids 203 were then washed (3 x 1 min in PBS and 6 x 1 min in water) before negative staining with 2% (w/v) 204 uranyl acetate for 10 min. Surplus staining was removed from grids and allowed to air dry before EV 205 samples were examined in a Philips CM12 TEM (FEI UK Ltd) at 80 kV. 206
Characterisation of EVs 207
Flow cytometry was used to assess the surface adhesion molecule profile of HECVs incubated at both 208 normoxia and hypoxia, and their corresponding EVs. Antibodies used for cytometric analysis were to set the EV gate, and were distinguishable as three distinct populations. HECVs were analysed for 217 forward scatter area and side scatter area whilst EVs were run on forward scatter area and side scatter 218 area that were set to logarithmic scale. Acquisition was terminated upon recording 10,000 events, 219 gated based on their forward scatter and side scatter characteristics. Fluorescence minus one (FMO) 220 stains were used to set the positive gates for each antibody. Appendix Figure A3 Time-resolved fluorescence was used to assess the surface protein and content of the isolated EVs 223 derived from both normoxia and hypoxia, as described previously [44] . 1x10 9 EVs were loaded onto a 224 high protein binding 96-well plate (Greiner Bio-One, Germany) overnight at 4°C, before non-specific 225 sites were blocked with 1% BSA (R&D Systems) for two hours. EVs were permeabilised using a 
Effect of hypoxia on EV size, concentration and distribution 243
Hypoxia exposure (1%, 2% and 5% O2) enhanced EV production in comparison to HECVs 244 maintained at normoxia (1% O2: 1766 ± 63.4 EVs/cell, 2% O2: 1179 ± 59 EVs/cell, 5% O2: 659 ± 48 245 EVs/cell vs 21% O2: 133 ± 15 EVs/cell, Figure 1A , p < 0.001). However, 10% and 20% O2 did not 246 change EV production (10% O2: 190.2 ± 40 EVs/cell, 20% O2: 218 ± 57 EVs/cell p>0.05) compared 247 to normoxia ( Figure 1A) . Hypoxic conditions did not affect EV mean size: 21% O2: 134 ± 8 nm; 1% 248 O2: 131 ± 27 nm; 2% O2: 133 ± 33 nm; 5% O2: 143 ± 38 nm; 10% O2: 133 ± 38 nm, 20% O2: 132 ± 249 30 nm, p> 0.05. Western blot analysis revealed the presence of HIF-1α in cells exposed to 1-5% O2 250 for 24 hours. HIF-1α was not detected in cells exposed to 10% or 20% O2 ( Figure 1B) . 251
On assessment of EV size distribution (split by 50 nm bin size for analysis), cells exposed to 1% O2 in 252 particular had an elevated EV concentration within a diameter range of 51 EVs/cell (p < 0.001 for all comparisons). EV distribution between 351 -1 µm was similar between 258 normoxic and hypoxic cells, p > 0.05 ( Figure 2) . 259
Cells incubated in normoxia exposed to the hypoxia mimetic agent desferrioxamine (100 µM) 260 produced significantly higher EVs compared to cells exposed to normoxia alone (1212 ± 109 EVs/cell 261 vs 133 ± 15.2 EVs/cell, p < 0.001). The addition of desferrioxamine to cells already exposed to 262 hypoxia (1% O2) had no influence on EV production compared to hypoxia exposure alone (1% O2: 263 1673 ± 60 EVs/cell vs 1% O2 DFO: 1733 ± 87 EVs/cell, p > 0.05) ( Figure 3A ). Chemically induced 264 hypoxia by desferrioxamine was confirmed by Western blot detection of HIF-1α in cells incubated in 265 normoxia. (Figure 3B) . 266
Viability and apoptosis 267
Cells exposed to 1% O2 had similar caspase 3/7 activity to control cells (688 ± 7 vs 612 ± 73, relative 268 luminescence units (RLU) p > 0.05). No difference was found in cell viability for cells exposed to 1% 269 
Morphology of HECV and HECV-derived-EVs. 274
Scanning electron microscopy confirmed the release of EVs from HECVs. Cells were homogenous 275 and approximately 10-15 µm in diameter. Appendix Figure A4A shows HECVs incubated in 276 normoxic (21% O2) conditions. Cells appear relatively dormant and have distinct cell boundaries. 277
Appendix Figure A4B shows HECV cells incubated in hypoxic conditions (1% O2) for 24 hours. 278
These cells appear rounded, producing a higher number of vesicles compared to the normoxic cells. 279
Transmission electron microscopy confirmed the presence of EVs isolated from HECVs incubated in 280 normoxia (Appendix Figure A4C ) and hypoxia (Appendix Figure A4D ). These EVs appear granular 281 and approximately 100-250 nm in diameter. 282
Characterisation of EVs 283
Flow cytometry confirmed the presence of VCAM-1, ICAM-1, PECAM-1, P-selectin and E-selectin 284 on HECVs which did not alter after hypoxia exposure (p > 0.05, Appendix Figure A5A ). The 285 presence of these adhesion molecules was reflected in the EVs. However these also did not change as 286 a function of hypoxia exposure (p > 0.05, Appendix Figure A5B ). There were no differences in the 287 proportion of annexin V positive EVs between hypoxia-derived EVs (11 ± 0.2%) and normoxia-288 derived EVs (11 ± 0.25%, p > 0.05). (Figure 2 ). HIF-1α was present in EVs isolated 294 from hypoxic HECVs and absent in those isolated from normoxia (21% O2; 115 ± 25 vs 1% O2; 295 10310 ± 520, p < 0.001) (Appendix Figure A6) . 296
Effect of silencing HIF-1α and HIF-2α 297
To confirm the role of HIF-1α and/or HIF-2α in the hypoxic enhancement of EV release, HECVs 298 were transfected with a siRNA targeting either HIF-1α, or HIF-2α. Cells transfected with HIF-1α 299 siRNA failed to show an enhancement in EV release following hypoxia compared to cells transfected 300 with control siRNA or cells exposed to hypoxia alone (HIF-1α siRNA in 1% O2: 243 ± 20 EVs/cell, 301 control siRNA in 1% O2: 1680 ± 473 EVs/cell, 1% O2:1680 ± 250 EVs/cell, p < 0.001) ( Figure 4A ). 302 EV production in cells transfected with HIF-1α siRNA in hypoxia was similar to that of the normoxia 303 control (158 ± 38 EVs/cell, p >0.05). HECVs were also transfected with HIF-2α siRNA. Unlike HIF-304
1α siRNA transfection, HIF-2α silencing had no effect on EV production compared to cells 305 transfected with control siRNA or exposed to hypoxia alone (HIF-2α siRNA in 1% O2: 1549 ± 46 306 EVs/cell, control siRNA in 1% O2: 1608 ± 69 EVs/cell, 1% O2:1774 ± 132 EVs/cell, p < 0.05. 307
Western blotting confirmed that cells transfected with HIF-1α and HIF-2α siRNA successfully 308 inhibited gene expression, whilst the control siRNA had no impact on HIF-1α/-2α expression ( Figure  309 4C, 4D). 310
Effect of sodium nitrite on EV production 311
To assess the effect of NO on the hypoxia-mediated enhancement of EV production, HECVs were 312 treated with NaNO2. There was little evidence to suggest that NaNO2 had any effect on EV production 313 at 21% O2, (21% O2:132 ± 15 EVs/cell vs 21% O2 + NaNO2: 125 ± 19 EVs/cell, p >0.05). However, 314
NaNO2 significantly reduced the hypoxic enhancement of EV production (1% O2: 1859 ± 67 EVs/cell 315 vs. 1% O2 + NaNO2: 905 ± 78 EVs/cell, p <0.001). Treatment of HECVs in hypoxia with allopurinol 316 in addition to NaNO2 attenuated the NaNO2-induced suppression of hypoxia-mediated EV release, 317 (1% O2 + NaNO2; 905 ± 78 EVs/cell vs 1% O2, NaNO2 + Allopurinol; 1414 ± 141 EVs/cell, p 318 <0.001). Allopurinol alone had no effect on EV production in hypoxia (1824 ± 69 EVs/cell, p > 0.05 319 ( Figure 4B ). The NO donor S-Nitrosoglutathione (GSNO) also significantly reduced EV production in 320 hypoxia (896 ± 27 EVs/cell, p < 0.001) ( Figure 5A ). Western blots confirmed that NaNO2 addition in 321 hypoxia reduced the expression of HIF-1α. The addition of allopurinol in the presence of NaNO2 322 appeared to restore HIF-1α expression in HECVs ( Figure 5B) . 323
Effect of hypoxia and sodium nitrite on EV production in HUVECs 324
In order to validate our findings in the HECV cell line, the effect of hypoxia and sodium nitrite on EV 325 production was also assessed in HUVECs. NaNO2 had no effect on EV production in normoxia (21% 326 O2: 43 ± 5.6 EVs/cell vs 21% O2 + NaNO2: 41 ± 4 EVs/cell, p > 0.05). Hypoxia greatly enhanced EV 327 production compared to normoxia (1% O2: 291 ± 23 EVs/cell vs 21% O2: 43 ± 6 EVs/cell, p < 0.001). 328
Furthermore, the addition of NaNO2 significantly reduced EV production in hypoxia (1% O2 + 329 NaNO2: 153 ± 11 EVs/cell vs 1% O2: 291 ± 23 EVs/cell, p < 0.001) ( Figure 6A ). Western blots 330
confirmed that NaNO2 addition in hypoxia reduced the expression of HIF-1α ( Figure 6B) . 331
Discussion 332
Our study shows that hypoxia-induced enhancement in EV production is mediated by HIF-1α in 333 endothelial cells. We extend these observations to show that NO2alleviates EV production selectively 334 during hypoxia at least in part by reduction to NO via xanthine oxidoreductase, in turn favouring the 335 oxygen sensitive degradation of HIF-1α and subsequent suppression of HIF-mediated EV release. 336
During pathological conditions cellular O2 levels can often be insufficient to meet physiological 337 demands. The resulting hypoxia is an important feature of cardiovascular disease, sleep apnoea, and 338 cancer and is associated with poor patient outcomes [45] . Endothelial cells exposed to hypoxia for 24 339 hours demonstrated enhanced EV production at 5% O2 and lower. This is in accordance with previous 340 studies which have demonstrated that hypoxia is associated with increased endothelial-derived EV 341 production in vivo [16, 17] . Arterial blood pO2 is normally within the range 10-14% O2 (75-100 342 mmHg), with venous levels approximately 4-5.5% O2 (30-40 mmHg). At an arterial O2 of 8% (60 343 mmHg) there is a steep decline in oxygen saturation, and a human would require supplemental 344 breathing, whereas <4% O2 (26 mmHg) can be considered extreme hypoxia [46] . Given these 345 reference ranges, we rationalised 5% O2 in our studies represents an accurate model of a hypoxic 346 condition for cells in culture, whereas less than 1% O2 reflects severe hypoxia. 347
Endothelial EV signalling has been shown to enhance activation and adhesion of platelets, leading to 348 the formation of a thrombus [47] . Studies have shown that increased EV release by activated 349 endothelial cells was associated with cardiovascular events in patients with stroke history [48] . It 350 remains unclear whether the pathological effects of these vesicles are due to differences in biological 351 cargo compared to vesicles released under resting conditions, or simply due to an increased number of 352 vesicles being produced. In our studies, we failed to measure a difference in numerous adhesion 353 molecules between vesicles released from cells in hypoxia compared to cells in normoxia. 354
Interestingly, we found HIF-1α was present in our EV sample, and was elevated under hypoxic 355 conditions, potentially allowing for paracrine signalling to nearby cells. Previous studies have shown 356 that nuclear translocation is not required for HIF-1α stabilization after its translation in the cytoplasm 357
[49], and thus may be packaged into EV during their formation via the classical pathway of exosome 358 formation. This pathway is governed by the endosomal sorting complex required for transport 359 (ESCRT), which orchestrates the formation of intraluminal vesicles within multivesicular bodies 360 following invagination of the cells plasma membrane [50] . Notably, we were unable to detect HIF-1α 361 in EVs derived from HIF-1α siRNA treated cells. 362
Consistent with previous reports in breast cancer cell lines [51] we provide evidence that HIF-1α is 363 pivotal in the hypoxia-induced enhancement of EV release in endothelial cells. In contrast, HIF-2α 364 had no influence on hypoxic EV production. Thus, hypoxia-mediated EV production may utilise 365 common cellular pathways regardless of the cell type. HIF-1α is thought to be involved in acute 366 hypoxia (2-24 hours), with HIF-2α involved in cellular adaptation to chronic hypoxia (>24 hours) 367 [52, 53] . A third HIF isoform, HIF-3α, also regulates the cellular response to hypoxia but was not 368 studied here. HIF-3α lacks the transactivation domain found in both HIF-1α and HIF-2α isoforms, and 369 is said to be a negative regulator of HIF-1α and HIF-2α induced gene expression [54] . 370
Acute hypoxia has been shown to increase calcium to levels similar to those observed during agonist 371 stimulation of endothelial cells, but too low to cause apoptosis or a reduction in viability [55] . The 372 mechanism of EV release by cells is still not fully characterised, although it is known to be dependent 373 on a rise in cytosolic calcium, and subsequent activation of calpain and protein kinases, allowing 374 cytoskeletal remodelling, translocation of phosphotidylserine, and enhanced permeability to 375 potassium with associated osmotic effects [56] [57] [58] [59] [60] . Indeed, HIF-1α activation has recently been 376
shown to permit cytoskeleton reorganization in endothelial cells [61] . Furthermore, RAB22A has 377 previously been identified as a potential mediator of HIF-1α induced EV release. RAB22A is a small 378 GTPase involved in trafficking between endosomal compartments, which is localised to budding EVs 379
[62]. A study by Wang et al showed expression of this GTPase was HIF-1α mediated, with RAB22A 380 knockdown completely eliminating the increase in EV production in hypoxia [63] . could therefore explain the increase in EV generation seen in this study. 390
To our knowledge this is the first study to demonstrate that NO alleviates the hypoxic enhancement of 391 EV production in endothelial cells, through the hypoxia-selective reduction of NO2to NO via 392 xanthine oxidoreductase. This reduction was observed in both an endothelial cell line (HECVs) and 393 primary endothelial cells (HUVECs). This observation is supported by previous work which showed 394 impaired NO production induces endothelial EV production in vitro [32] . In contrast to the 395 constitutively expressed β-subunit of HIF, HIF-1α is an oxygen-regulated subunit. Numerous factors 396 have been shown to modulate HIF-1α activation and stabilisation in general, including NO [69]. NO2 -397
represents a bioactive "storage pool" for NO under certain conditions, such as hypoxia. This pathway, 398
dubbed the "nitrate-nitrite-nitric oxide pathway", has been said to complement the L-arginine-eNOS 399 pathway perfectly, ensuring NO production continues during conditions where oxygen-dependent 400 eNOS activity is compromised. Indeed we, and others, have previously shown that NO2administered 401 intravenously can protect against vascular reperfusion injury [70, 71] . 402
The regulation of HIF-1α by NO in hypoxia involves the mitochondrial cytochrome c oxidase (CcO), 403 which plays a central role in oxidative phosphorylation and ATP synthesis. NO can readily modulate 404 the activity of CcO and therefore its O2 consumption. In hypoxia, competitive binding of NO inhibits 405
CcO allowing the redistribution of intracellular O2, leading to increased O2 availability for prolyl 406 hydroxylation and subsequent degradation of HIF-1α, which has been shown by numerous studies 407
[30,31,69]. Collectively, our data suggest that although HIF-1 appears to be the master hypoxic 408 regulator which governs hypoxia-induced EV release, under hypoxic conditions NO2is metabolised 409 to NO, promoting the degradation of HIF-1α and subsequent suppression of EV release. Interestingly, 410 HIF-1α can enhance NO production via upregulation of inducible nitric oxide synthase (iNOS), 411 highlighting a potential negative feedback mechanism [72, 73] . 412
Treatment of endothelial cells with allopurinol, in the presence of NaNO2, largely inhibited the NO2-413 attributed suppression of EV production. This confirms that under hypoxic conditions, xanthine 414 oxidoreductase plays an important role in the reduction of NO2to NO. However, the presence of 415 allopurinol failed to completely restore EV production seen in hypoxia alone, and it is therefore likely 416 that multiple mechanisms, including mitochondrial reduction and aldehyde dehydrogenase play a role 417 in reducing NO2to NO in endothelial cells [74] . 418
In summary, this study suggests a novel means by which inorganic nitrite (NO2 -) alleviates the 419 hypoxic enhancement in EV production. Future studies should further elucidate which downstream 420 targets of HIF-1α may be responsible for the increase in EV production, and investigate whether 421 enhancing NO bioavailability affects EV levels in clinical models of ischaemia. 422 conditions. Lane 1: 21% O2. Lane 2: 21% O2, NaNO2. Lane 3: 1% O2. Lane 4: 1% O2, NaNO2. Lane 5: 668 1% O2, NaNO2 and allopurinol. Results represent [n = 5]. Each sample was analysed in quintuplicate 669 and the mean was used in further analysis. Data are expressed as mean ± SEM. **, *** reflects p< 670 0.01, and p< 0.001 respectively. 671 672 Figure 6 . The effect of hypoxia and sodium nitrite on EV production in HUVECs. (A) EVs produced by HUVECs following exposure to hypoxia and/or NaNO2. (B) Western blotting showing the expression of HIF-1α following exposure to hypoxia and/or NaNO2. Lane 1: 1% O2. Lane 2: 1% O2 + NaNO2. Lane 3: 21% O2. Lane 4: 21% O2 + NaNO2. Results represent [n=5]. Each sample was analysed in quintuplicate and the mean was used in further analysis. Data are expressed as mean ± SEM. *** reflects p< 0.001.
